{"entity":{"id":"nct06414460","kind":"trial","name":"Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of ISM3412 in advanced solid tumours, run by InSilico Medicine Hong Kong Limited, now recruiting.","summary":"Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT06414460 by InSilico Medicine Hong Kong Limited, with 146 participants planned, started 2025-04-25 and due to reach its primary completion in 2028-03-31. Interventions recorded: ISM3412.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06414460","url":"https://clinicaltrials.gov/study/NCT06414460"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["insilico-medicine"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06414460","phase":"1/2","setting":"A Phase 1/2, Open-Label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Preliminary Efficacy of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors","sponsor":"InSilico Medicine Hong Kong Limited","started":"2025-04-25","startedType":"actual","enrolled":146,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06414460/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"insilico-medicine","kind":"company","name":"Insilico Medicine","route":"/companies/insilico-medicine/"}]}}